LUCENTIS offers patients efficacy across multiple indications1
The anti-VEGF with the broadest range of retinal indications1
Click the button below to see the key efficacy data for LUCENTIS in the treatment of neovascular (wet) age-related macular degeneration (AMD).
Resources to help you with your LUCENTIS patients
We cover a variety of topics about a-VEGF patients, treatment and service impact due to COVID-19 in a variety of webinars and podcasts.
*LUCENTIS 0.2 mg is indicated in preterm infants for:1
The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
DMO, diabetic macular oedema; CNV, choroidal neovascularisation; HCP, healthcare professional; PDR, proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; RWE, real-world evidence; T&E, treat & extend;‡ VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration;
Reference
- Lucentis (ranibizumab) Summary of Product Characteristics, July 2020.
- Novartis Data on File. Novartis Pharma AG, LUCDOF21-002, October 2019.
- Novartis Data on File. Novartis Pharma AG, LUCDOF21-003, October 2019.
- Dorairaj E, et al. Ranibizumab in diabetic macular oedema: 2 year audit data. Presented at ESCRS 2017, Maastricht, The Netherlands.
- Prakash, P, et al. To determine the efficacy of treatment of Ranibizumab over a period of 5 years in patients with DMO at PAH, Harlow, presented at Royal College of Ophthalmology congress 2021.
- Mitchell P, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020;15(6):32492069.
Rate this content:
UK | December 2021 | 176510
